Most common uterine tumor is:-
35 yr old lady attends gynaec OPD with excessive bleeding since 6 months, not controlled with non hormonal drugs. USG and clinical examination reveals no abnormality. Next step is?
Most useful investigation in a 55-year-old postmenopausal woman with diabetes mellitus and hypertension who has presented with postmenopausal bleeding is:
A postmenopausal diabetic woman presents with bleeding per vaginum. The most likely diagnosis is :
Identify the pathological condition shown in the image:

An 18-year-old unmarried girl comes with complaints of heavy, prolonged bleeding during menses. Which among the following investigations is NOT usually advised?
Dysfunctional uterine bleeding (DUB) is best treated by:
A 32-year-old woman presents with irregular, heavy menstrual bleeding. After thorough evaluation including pelvic ultrasound, hormonal assays, coagulation profile, and endometrial sampling, no structural abnormalities, systemic disorders, or medication-related causes are identified. This clinical scenario is best described as:
A 45 year old woman presents with continuous vaginal bleeding for 15 days. Her bleeding should be controlled by:
A 20-year-old married woman anxious to get pregnant has cyclical cramps and sharp lower abdominal pain which lasts for 3 days starting from the day of her menstrual flow. Her menstrual periods are regular but heavy. On clinical examination, her pelvis is normal. The most probable diagnosis is
Explanation: ***Leiomyoma*** - **Leiomyomas**, also known as **fibroids**, are the most **common benign tumors of the uterus**. - They are composed of **smooth muscle cells** and can vary in size and location within the uterus. *Adenomyoma* - An **adenomyoma** is a benign uterine tumor characterized by the presence of **endometrial glands and stroma** within the myometrium. - While it is a uterine tumor, it is significantly **less common** than leiomyomas. *Endometrial cancer* - **Endometrial cancer** is a **malignant tumor** arising from the endometrium and is the most common gynecologic malignancy. - However, malignant tumors are generally **less common** than benign tumors like leiomyomas. *Leiomyosarcoma* - **Leiomyosarcoma** is a **rare and aggressive malignant tumor** of the smooth muscle tissue of the uterus. - It accounts for a very small percentage of uterine masses and is much less common than benign leiomyomas.
Explanation: ***Endometrial sampling*** - In a 35-year-old with **excessive uterine bleeding** not controlled by non-hormonal drugs and with normal imaging/clinical exam, endometrial sampling is crucial to **rule out endometrial hyperplasia or malignancy**. - This diagnostic step is essential before considering definitive treatments, as it provides a **histological diagnosis** of the endometrial lining. *Hysterectomy* - Hysterectomy is a **definitive surgical treatment** for excessive bleeding, but it is typically reserved for cases where conservative or less invasive treatments have failed, or if there's a serious underlying pathology like malignancy. - It involves removing the uterus and is a **major surgery** with potential complications, thus not usually the first step given an otherwise normal examination and imaging. *Endometrial ablation* - Endometrial ablation is a procedure to destroy the lining of the uterus, aiming to **reduce or stop menstrual bleeding**. - It is a treatment option for **abnormal uterine bleeding (AUB)**, but it's typically performed after other diagnostic steps (like endometrial sampling) have ruled out malignancy or high-risk hyperplasia, and when conservative medical management has failed. *Hormonal therapy* - Hormonal therapy (e.g., combined oral contraceptives, progestin-only pills, levonorgestrel-releasing intrauterine device) is often a **first-line medical treatment** for excessive uterine bleeding. - However, the question states that non-hormonal drugs have already failed, and without a clear diagnosis, initiating new hormonal therapy without **evaluating the endometrium** is not the next best step for persistent bleeding.
Explanation: ***Endometrial biopsy*** - This is the **most crucial investigation** for postmenopausal bleeding to rule out **endometrial cancer** or **hyperplasia**, especially in a patient with risk factors like diabetes and hypertension. - An endometrial biopsy directly samples the **uterine lining** for histological examination, providing a definitive diagnosis of any abnormal tissue changes. *Pap test* - A Pap test, or **Papanicolaou test**, primarily screens for **cervical cancer** by examining cells from the cervix. - It is **not effective** for detecting uterine (endometrial) abnormalities or cancer, which is the main concern with postmenopausal bleeding. *Transvaginal ultrasound examination* - While useful for assessing **endometrial thickness** and identifying structural abnormalities like polyps or fibroids, it is **not diagnostic** on its own. - An abnormal ultrasound finding, such as a thickened endometrium (usually >4-5mm in postmenopausal women), would typically prompt an endometrial biopsy for definitive diagnosis. *CA-125 blood test* - **CA-125** is a tumor marker primarily used for monitoring the response to treatment in **ovarian cancer** and can be elevated in other conditions like endometriosis or fibroids. - It is **not a screening tool** for endometrial cancer and is **not specific or sensitive enough** to be the primary investigation for postmenopausal bleeding.
Explanation: ***Malignancy of the endometrium*** - **Postmenopausal bleeding** is the classic presenting symptom of **endometrial cancer**, which must be ruled out in all such cases. - **Diabetes** is a known risk factor for endometrial cancer, along with obesity, hypertension, and unopposed estrogen exposure. *Malignancy of the vulva* - Vulvar cancer typically presents with a **pruritic lesion**, lump, or ulcer on the vulva, rather than solely with vaginal bleeding. - While bleeding can occur from an advanced vulvar lesion, it is not the primary or most common presentation for new onset postmenopausal bleeding. *Malignancy of the cervix* - Cervical cancer often presents with **postcoital bleeding** or irregular vaginal bleeding in premenopausal women, or less commonly, postmenopausal bleeding. - Screening with **Pap smears** typically detects precancerous changes or early cervical cancer, making it less likely to be the first presentation with postmenopausal bleeding in a well-screened population. *Malignancy of the ovary* - Ovarian cancer is often asymptomatic in its early stages and presents with non-specific symptoms like **abdominal distension**, bloating, or pelvic pain. - **Vaginal bleeding** is not a typical symptom of ovarian cancer, unless the tumor is very large, involves adjacent structures, or is a hormone-producing tumor.
Explanation: ***Adenomyoma*** - The image distinctly shows **endometrial glands and stroma** embedded within the **myometrium** (smooth muscle layer of the uterus), which is the hallmark of adenomyoma [1]. - This condition is essentially a localized form of **adenomyosis**, presenting as a mass [1]. *Intramural fibroid* - An intramural fibroid (leiomyoma) is a **benign tumor of smooth muscle cells**, typically showing a proliferation of uniform spindle cells with characteristic swirling patterns [2]. - It would lack the presence of **endometrial glands and stroma** within the lesion [2]. *Endometriosis* - Endometriosis involves the presence of **endometrial tissue outside the uterus**, such as on the ovaries, peritoneum, or bowel. - While it involves similar tissue, its location is **extrauterine**, whereas the image depicts a lesion within the uterine wall. *Myomatous polyp* - A myomatous polyp (or submucosal fibroid) is a **fibroid that protrudes into the uterine cavity**, often covered by endometrial tissue [2]. - The image does not show a polypoid growth extending into the cavity but rather glandular tissue directly within the muscle wall. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. Common Clinical Problems From Female Genital Tract Disease, pp. 475-476. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Female Genital Tract, pp. 1024-1025.
Explanation: ***Dilatation and curettage*** - This is an **invasive surgical procedure** used diagnostically and therapeutically for heavy uterine bleeding, but it is generally *not* the initial or routinely advised investigation for an 18-year-old unmarried girl with heavy menstrual bleeding. - In a young, unmarried patient, less invasive methods are preferred unless other investigations point to a structural abnormality requiring tissue diagnosis or therapeutic intervention. *Urine pregnancy test* - A urine pregnancy test is **essential** to rule out pregnancy-related complications (e.g., ectopic pregnancy, miscarriage) as a cause of heavy vaginal bleeding, even in unmarried individuals. - **Abnormal uterine bleeding** can be the presenting symptom of an early pregnancy loss. *Coagulation profile* - Heavy and prolonged bleeding, especially from a young age (as suggested by "18-year-old girl"), raises suspicion for an **underlying coagulopathy** (e.g., Von Willebrand disease). - A coagulation profile (including PT, aPTT, platelet count, and sometimes specific factor assays) is crucial to **assess bleeding risk** and guide management. *Ultrasound uterus and adnexa* - An ultrasound is a **non-invasive imaging technique** that can identify structural causes of abnormal uterine bleeding, such as **fibroids, polyps, adenomyosis**, or ovarian pathologies. - It helps in assessing the **uterine lining and ovarian morphology**, which is important in evaluating the cause of heavy menstrual bleeding.
Explanation: ***Progestogen*** - **Progestogen** therapy helps stabilize the **endometrium**, reducing excessive or irregular bleeding in DUB by counteracting unopposed estrogen. - It induces a more organized shedding of the uterine lining, which can regularize the menstrual cycle. *Curettage of uterus* - While **curettage** can provide temporary relief by removing the endometrial lining, it is primarily a diagnostic procedure to rule out pathology rather than a primary long-term treatment for DUB. - It does not address the underlying hormonal imbalance that causes DUB, leading to a high recurrence rate of symptoms. *Estrogen* - **Estrogen** therapy alone is generally not used to treat DUB because unopposed estrogen is often the cause of DUB, leading to **endometrial overgrowth** and irregular shedding. - Administering estrogen without a progestin could exacerbate the condition and increase endometrial proliferation. *Clomiphene* - **Clomiphene** is an anti-estrogen medication primarily used to induce **ovulation** in women with infertility. - It is not indicated for the management of dysfunctional uterine bleeding or for regulating menstrual cycles directly.
Explanation: ***No identifiable causes present*** - As per its definition, **dysfunctional uterine bleeding (DUB)** is diagnosed when no structural, systemic, or iatrogenic etiology for abnormal uterine bleeding can be found. - The diagnosis of DUB is essentially a **diagnosis of exclusion**, meaning it is made after ruling out other potential causes of bleeding. *Presence of systemic causes* - If systemic causes, such as **coagulation disorders** or **thyroid dysfunction**, are identified, the bleeding is attributed to these conditions, and it is not considered DUB. - DUB specifically implies that systemic factors have been investigated and found to be absent or not the primary cause of the bleeding. *Presence of iatrogenic causes* - **Iatrogenic causes** refer to abnormal bleeding induced by medical interventions, such as specific medications (e.g., anticoagulants, hormonal contraceptives) or medical devices (e.g., IUDs). - If such causes are identified, the bleeding is categorized accordingly, and the diagnosis of DUB is excluded. *Presence of identifiable organic causes* - **Organic causes** include structural abnormalities of the uterus or reproductive tract, such as **fibroids**, **polyps**, **adenomyosis**, or **malignancy**. - The presence of any of these identifiable pathology rules out DUB, as DUB is by definition non-organic.
Explanation: ***Synthetic progestogens*** - **Synthetic progestogens** are the **classic first-line medical treatment** for dysfunctional uterine bleeding (DUB) in the perimenopausal age group. - They work by **stabilizing the endometrium**, counteracting unopposed estrogen effects, and inducing organized withdrawal bleeding. - For **continuous moderate bleeding**, cyclic or continuous progestogens (e.g., norethisterone 5 mg BD for 21 days) are effective and non-invasive. - This represents the **traditional textbook approach** for anovulatory DUB management. *Testosterone propionate* - **Testosterone propionate** is an androgen with no role in managing dysfunctional uterine bleeding in women. - Its use is limited to male hypogonadism and specific anabolic requirements. *Curettage followed by progestogens* - While **curettage (D&C)** is both diagnostic and therapeutic, it is an **invasive procedure**. - In clinical practice, especially for a **45-year-old woman**, endometrial sampling is often warranted to rule out hyperplasia or malignancy, making this a reasonable clinical approach. - However, **medical management with progestogens alone** is traditionally considered first-line when the patient is hemodynamically stable and malignancy risk is low. - This option represents sound clinical practice but is not the classic "first choice" in exam contexts. *Conjugated equine oestrogens* - **High-dose estrogens** (25 mg IV every 4-6 hours) are actually used for **acute severe bleeding** and can stop bleeding within 24 hours by rapidly proliferating the endometrium. - However, for **continuous moderate bleeding** over 15 days in a perimenopausal woman, estrogen alone would not address the underlying issue of **unopposed estrogen** causing anovulatory cycles. - Estrogen is reserved for acute emergency management, not for the scenario described in this question.
Explanation: ***Primary dysmenorrhoea*** - This is the **most probable diagnosis** given the classic presentation of **cyclical cramping pain starting on day 1 of menstruation** lasting 3 days. - Primary dysmenorrhea is caused by **excessive prostaglandin production** from the endometrium, leading to uterine cramping and can be associated with **heavy menstrual bleeding**. - The **normal pelvic examination** is a key feature distinguishing primary from secondary causes of dysmenorrhea. - Typically affects young women in their **late teens to early 20s**, shortly after menarche when ovulatory cycles are established. *Endometriosis* - While endometriosis causes cyclical pain, the pain typically begins **1-2 days before menstruation** rather than starting precisely on day 1. - Associated symptoms often include **dyspareunia, dyschezia, and infertility**, which are not mentioned in this case. - Though pelvic examination can be normal in early endometriosis, the **pain timing pattern** does not fit the classic presentation. *Adenomyosis* - Characterized by **endometrial tissue within the myometrium**, typically presents with a **diffusely enlarged, tender, boggy uterus** on examination. - More common in women over 30 years, particularly those with **previous pregnancies**. - The patient's **normal pelvic examination** and young age make adenomyosis unlikely. *Uterine leiomyomata* - These **benign fibroids** typically cause heavy menstrual bleeding with **pressure symptoms** rather than severe cyclical cramping pain. - Usually result in an **irregularly enlarged uterus** on pelvic examination. - The patient's **normal pelvic examination** excludes this diagnosis.
Get full access to all questions, explanations, and performance tracking.
Start For Free